Spectral Medical’s Chief Medical Officer, Dr. John Kellum, to be the Featured Speaker in Webinar Hosted by Sepsis Alliance
TORONTO, July 26, 2022 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that Dr. John Kellum, Spectral’s Chief Medical Officer, will be the featured speaker in a webinar hosted by Sepsis Alliance during Sepsis Awareness Month.
| Title: | Endotoxins: the “Missing Link” in the Pathogenesis of Sepsis. | |
| Date: | September 15, 2022 | |
| Time: | 2:00 – 3:00 pm ET / 11:00 am – 12:00 pm PT | |
| Description: | Sepsis is the dysregulated and often life-threatening host response to infection that can lead to tissue damage, organ failure, and death. Endotoxemia could be the “missing link” in the pathogenesis of these cases, as endotoxin appears to represent an important molecular phenotype of sepsis with unique clinical manifestation and high mortality. In this webinar, learners will review identification and measurement of endotoxin in the bloodstream and gain a better understanding of how endotoxin can contribute to sepsis and organ dysfunction. |
Interested parties can register for the webinar here.
About Spectral
Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.
PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxemic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year.
Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum. SAMI is targeting the acute RRT market, while DIMI is targeting the chronic RRT market. Dialco is currently pursuing regulatory approval for U.S. in-home use of DIMI, which is based on the same RRT platform as SAMI, but will be intended for home hemodialysis use. DIMI recently received its FDA 510k clearance for use in hospital and clinical settings, and obtained its Health Canada license for use within Canadian hospitals, clinics and in home.
Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com.
Forward-looking statement
Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral’s senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
Contact:
| Mr. Blair McInnis | Mr. Ali Mahdavi | David Waldman/Natalya Rudman |
| CFO | Capital Markets & Investor Relations | US Investor Relations |
| Spectral Medical Inc. | Spinnaker Capital Markets Inc. | Crescendo Communications, LLC |
| 416-626-3233 | 416-962-3300 | 212-671-1020 |
| bmcinnis@spectraldx.com | am@spinnakercmi.com | edt@crescendo-ir.com |
